ERBB2 and gastric cancer: Given that this condition often designates a very advanced stage of the gastric cancer, and that the best overall survival of patients with metastatic gastric cancer is 13.8 months in patients with HER2 expression treated with Trastuzumab plus chemotherapy [23], the prognosis is usually poor and the survival doesn’t exceed one year.